Smithkline Beecham (SBH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Smithkline Beecham (SBH)

SBH 9.630

-4.4%

Jul 15 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike Battin who wrote (48)	7/10/1998 12:01:00 AM
From: Henry Niman	of 61

Today Dow Jones had an extensive article on SBH and they did mention the new TZD under development for Type II diabetes. I've linked it to the merger table at home.att.net Tomorrow's Science will have an exciting paper on a G-CSF mimic discovered by scientists at SBH and LGND. I have updated the G-CSF (Neupogen) mimic table at home.att.net to include links to the press release, abstract of the Science article, commentary in Science, and several upcoming abstracts. The current SBH/LGND alliance targets hematopoietic growth factors like Epogen and Neupogen, but recently Leptin was added to the list of targets and I suspect that the target list will continue to grow. Tomorrow's paper is a "proof of principle" that can be applied to virtually any polypeptide hormone (interferons, interleukins, or growth factors) and it is a major event.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next